Federal Air Surgeon Dr. Susan Northrup's conversation with AOPA during Mental Health Awareness Month outlines a deliberate, multi-year effort by the FAA to restructure how mental health conditions are handled within the medical certification system. Since taking the position in 2021, Northrup has guided the agency through a period of significant policy evolution, following recommendations from the Mental Health and Medical Clearance Aviation Rulemaking Committee. The core thrust of those changes is transparency and consistency: directing pilots to the publicly available Guide for Aviation Medical Examiners so they arrive at their appointments informed, reducing uncertainty that historically drove pilots to avoid disclosure altogether. The FAA's medical application volume has grown substantially in the post-pandemic period, climbing from approximately 385,000 annual applications pre-COVID to roughly 450,000, with special issuances rising from 10 to 12 percent of that total — a trend that makes efficient, standardized processing more operationally critical than ever.
Northrup frames the FAA's current approach around three principles she calls the "three E's": educate, early intervention, and evolution of standards. The early intervention pillar carries particular weight from a safety perspective. A study conducted by Dr. William Hoffman found that while the average American seeks care for acute cardiac symptoms within 48 hours, the average pilot waits approximately four weeks — a delay with potentially irreversible consequences. Northrup draws a direct parallel to mental health: pilots who fear losing their medical certificate consistently delay or forego treatment, allowing manageable conditions to deteriorate into acute crises. The clinical concern she raises is not primarily about diagnosis reporting; it is about preventing pilots from reaching a threshold where a condition has already caused significant harm, either to themselves or, by extension, to the safety of flight operations. For working pilots, the message is that early, proactive engagement with mental health care — ideally before a formal diagnosis is established — is both clinically sound and strategically advantageous in navigating the certification system.
On the procedural side, the FAA has implemented several concrete pathways that reduce the certification burden for specific mental health diagnoses. Thirteen conditions now qualify for Aviation Medical Examiner self-issuance, provided the applicant has been off medication for two years, achieved stability without exceeding two medications during treatment, and does not fall into a restricted diagnostic category. Worksheets have been developed for PTSD and adjustment disorder to standardize the evaluation process. For ADHD specifically, a streamlined pathway exists for individuals who have been off medication for four years and demonstrate sustained occupational or academic functioning — though the standard ADHD certification pathway through Oklahoma City remains available for those who do not meet that threshold. Medication-treated ADHD remains prohibited under current standards, though Northrup acknowledged that re-examining that policy is an active recommendation, citing concerns about the short half-life of currently available U.S. stimulant medications and the symptom rebound risk associated with missed doses.
For professional and corporate flight departments, these developments carry direct operational relevance. Pilots flying under Part 121, 135, or Part 91K operations who have been managing mental health conditions — or who are reluctant to seek care — now have a more navigable regulatory environment than existed five years ago. The expansion of AME self-issuance authority reduces the time and administrative burden of special issuance processing for qualifying conditions, which translates to shorter grounding periods and less financial exposure for operators dealing with crew availability. At the same time, the ADHD medication question remains unresolved, and pilots managing that condition with pharmacological treatment have no current certification pathway — a meaningful gap given the rising prevalence of ADHD diagnoses in the pilot population and the broader workforce. The direction of policy, however, is clearly toward greater accommodation, with Northrup expressing cautious optimism about longer-acting ADHD medications under development in the United States that could eventually address the dosing-reliability concerns that currently preclude approval.